Payment overview · 2025
General Payments
$398.97
17 reported records · 7 companies
Healthcare provider profile · identity verified
Keely E Vaughan, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · MARTIN, TN · NPI 1780060319
Verified facts
What the public records show
CMS Open Payments records show Keely E Vaughan, PA-C received $398.97 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.47 | 34.5% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.05 | 19.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.36 | 15.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.48 | 12.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 11.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $15.36 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12.25 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $353.97 | 16 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.47 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.05 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $60.36 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $12.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 75 |
| Furosemide | Furosemide | 269 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 58 |
| Trazodone Hcl | Trazodone Hcl | 263 | 44 |
| Alprazolam | Alprazolam | 232 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 27 |
| Sertraline Hcl | Sertraline Hcl | 176 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 56 |
| Potassium Chloride | Potassium Chloride | 162 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 35 |
| Baclofen | Baclofen | 149 | suppressed |
| Mirtazapine | Mirtazapine | 143 | 18 |
| Lisinopril | Lisinopril | 140 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 136 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 41 |
| Omeprazole | Omeprazole | 130 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 24 |
| Buspirone Hcl | Buspirone Hcl | 107 | 20 |
| Gabapentin | Gabapentin | 100 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 20 |
| Famotidine | Famotidine | 92 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 22 |
| Losartan Potassium | Losartan Potassium | 85 | 27 |
| Meloxicam | Meloxicam | 82 | 26 |
| Divalproex Sodium | Divalproex Sodium | 81 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 81 | 25 |
| Simvastatin | Simvastatin | 76 | 24 |
| Lorazepam | Lorazepam | 75 | 11 |
| Cartia Xt | Diltiazem Hcl | 65 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 50 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 18 |
| Ozempic | Semaglutide | 59 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 56 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Tramadol Hcl | Tramadol Hcl | 55 | 14 |
| Allopurinol | Allopurinol | 52 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Eliquis | Apixaban | 48 | suppressed |
| Letrozole | Letrozole | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 25 |
| Prednisone | Prednisone | 46 | 39 |
| Cephalexin | Cephalexin | 44 | 35 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Glimepiride | Glimepiride | 44 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 18 |
| Nystatin | Nystatin | 41 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Carvedilol | Carvedilol | 37 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Jardiance | Empagliflozin | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 26 |
| Olanzapine | Olanzapine | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 11 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 14 |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.97 · 17 records | Novo Nordisk Inc | Auvelity, Dexcom G6 Transmitter, FARXIGA, Hillrom - Cardiac Ambulatory Monitor, Ozempic, REXULTI, Rybelsus | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error